Aurora Cannabis has paid £2.1m in cash for 100% of the shares of Internod Pharma, an importer and wholesaler, and HAP Pharma, a licensed pharmacy, as it looks to service growing demand for medical cannabis from UK patients.
“We believe this transaction will allow us to fully leverage our operational, commercial and regulatory expertise to expand our market share,” said Miguel Martin, executive chairman and CEO of Aurora.
He said it would support a “consistent and reliable supply of high-quality medical cannabis products to UK patients.”
Read more: Medical cannabis: Is the pharmacy sector ready to roll?
Growing patient demand and increasingly “prescriptive regulatory standards” make the UK an “exciting opportunity for us,” he added.
“These companies provide Aurora with greater agility to more reliably serve UK patients.”
Aurora is currently scouting “further investment opportunities” to ramp up its distribution capacity in the UK to support “increasing patient demand” for medical cannabis products.
The business trades in both medical and consumer markets across Canada, Europe, Australia, and New Zealand.

